Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment

Cancer Research

Volumn 64, Issue 9, 2004, Pages 3209-3214

  Sonveaux, Pierre ^a   Dessy, Chantal ^a   Martinive, Philippe ^a   Havaux, Xavier ^b   Jordan, Bénédicte F ^c   Gallez, Bernard ^c   Grégoire, Vincent ^d   Balligand, Jean Luc ^a   Feron, Olivier ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b Cardiovascular Pathology Unit   (Belgium)

^c Biomedical Magnetic Resonance Unit   (Belgium)

^d Radiobiol and Radioprotection Unit   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERIOLE; ARTERY CONSTRICTION; ARTICLE; BLOOD FLOW; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; DRUG TUMOR LEVEL; ELECTRON SPIN RESONANCE; LASER DOPPLER FLOWMETRY; MALE; MOUSE; MUSCLE TONE; MYOGRAPHY; NONHUMAN; OXIMETRY; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASODILATATION;

ANIMALS; ARTERIOLES; ENDOTHELIN-1; MALE; MICE; MICE, INBRED C3H; MUSCLE TONUS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PEPTIDES, CYCLIC; RADIATION TOLERANCE; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION;

EID: 2342571715     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1291     Document Type: Article

References (42)

1. Keshet E, Ben Sasson SA. Anticancer drug targets: approaching angiogenesis. J Clin Investig 1999;104:1497-501.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.
4. Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Investig 1999;29:802-9.
5. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
6. Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol 1998;8:151-63.
7. Hirst DG, Hirst VK, Shaffi KM, Prise VE, Joiner B. The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol 1991;60:211-8.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68.
9. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80 (Suppl 1):57-64.
10. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000;48:565-70.
11. Fukumura D, Yuan F, Endo M, Jain RK. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 1997;150:713-25.
12. Hirst DG, Kennovin GD, Flitney FW. The radiosensitizer nicotinamide inhibits arterial vasoconstriction. Br J Radiol 1994;67:795-9.
13. Emerich DF, Snodgrass P, Dean RL, et al. Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy. J Pharmacol Exp Ther 2001;296:623-31.
14. Jordan BF, Gregoire V, Demeure RJ, et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62:3555-61.
15. Sonveaux P, Dessy C, Brouet A, et al. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery. FASEB J 2002;16:1979-81.
16. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999;59:3776-82.
17. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995;55:3564-8.
18. Bell KM, Prise VE, Chaplin DJ, Wordsworth S, Tozer GM. Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats. Int J Cancer 1997;73:283-9.
19. Bell KM, Chaplin DJ, Poole BA, Prise VE, Tozer GM. Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620. Int J Cancer 1999;80:295-302.
20. Tozer GM, Shaffi KM, Prise VE, Bell KM. Spatial heterogeneity of tumour blood flow modification induced by angiotensin II: relationship to receptor distribution. Int J Cancer 1996;65:658-63.
21. Thews O, Kelleher DK, Vaupel P. Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation. Br J Cancer 2000;83:225-31.
22. Shankar A, Loizidou M, Burnstock G, Taylor I. Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases. Br J Surg 1999;86:453-7.
23. Hahn JS, Braun RD, Dewhirst MW, et al. Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressure. Radiat Res 1997;147:185-94.
24. Kristensen CA, Roberge S, Jain RK. Effect of tumor necrosis factor alpha on vascular resistance, nitric oxide production, and glucose and oxygen consumption in perfused tissue-isolated human melanoma xenografts. Clin Cancer Res 1997;3:319-24.
25. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
26. Vaupel P, Hockel M. Tumor oxygenation and its relevance to tumor physiology and treatment. Adv Exp Med Biol 2003;510:45-9.
27. Kurbel S, Kurbel B, Kovacic D, et al. Endothelin-secreting tumors and the idea of the pseudoectopic hormone secretion in tumors. Med Hypotheses 1999;52:329-33.
28. Asham E, Shankar A, Loizidou M, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 2001;85:1759-63.
29. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2002;14:44-50.
30. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143-8.
31. Bertram JS, Janik P. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett 1980;11:63-73.
32. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take Clin Exp Metastasis 1985;3:281-94.
33. Sonveaux P, Brouet A, Havaux X, et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 2003;63:1012-9.
34. Donckier JE, Michel L, Van Beneden R, Delos M, Havaux X. Increased expression of endothelin-1 and its mitogenic receptor ETA in human papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2003;59:354-60.
35. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999;79:387-423.
36. Peng H, Matchkov V, Ivarsen A, Aalkjaer C, Nilsson H. Hypothesis for the initiation of vasomotion. Circ Res 2001;88:810-5.
37. Hill MA, Zou H, Potocnik SJ, Meininger GA, Davis MJ. Invited review: arteriolar smooth muscle mechanotransduction: Ca(2+) signaling pathways underlying myogenic reactivity. J Appl Physiol 2001;91:973-83.
38. Pohl U, Busse R. Differential vascular sensitivity to luminally and adventitially applied endothelin-1. J Cardiovasc Pharmacol 1989;13(Suppl 5):S188-90.
39. Mima T, Yanagisawa M, Shigeno T, et al. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 1989;20:1553-6.
40. Xie H, Bevan JA. Oxidized low-density lipoprotein enhances myogenic tone in the rabbit posterior cerebral artery through the release of endothelin-1. Stroke 1999;30:2423-9.
41. Huang A, Koller A. Endothelin and prostaglandin H2 enhance arteriolar myogenic tone in hypertension. Hypertension 1997;30:1210-5.
42. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.